A growing body of research on CNV provides a compelling rationale for undertaking a complementary sequencing approach to psychiatric disease. The era of high-throughput sequencing is now in full swing, with efforts currently under way to sequence exomes and whole genomes in all major psychiatric disorders (Girard et al., 2011; Najmabadi et al., 2011; O’Roak et al., 2011; Vissers et al., 2010; Xu et al., 2011). These efforts promise to capture a larger fraction of rare genetic variation and increase the proportion of genetic risk that can be explained.
